Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.

Détails

Ressource 1Télécharger: REF.pdf (142.67 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_06A919A7FBA1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.
Périodique
Annals of Oncology
Auteur⸱e⸱s
Italiano A., Penel N., Robin Y.M., Bui B., Le Cesne A., Piperno-Neumann S., Tubiana-Hulin M., Bompas E., Chevreau C., Isambert N., Leyvraz S., du Chatelard P.P., Thyss A., Coindre J.M., Blay J.Y.
ISSN
1569-8041
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
20
Numéro
3
Pages
425-430
Langue
anglais
Résumé
BACKGROUND: There are only scarce data about the benefit of adjunctive chemotherapy in patients with localized synovial sarcoma (SS). PATIENTS AND METHODS: Data from 237 SS patients recorded in the database of the French Sarcoma Group were retrospectively analyzed. The respective impact of radiotherapy, neo-adjuvant chemotherapy and adjuvant chemotherapy on overall survival (OS), local recurrence-free survival (LRFS) and distant recurrence-free survival (DRFS) were assessed after adjustment to prognostic factors. RESULTS: The median follow-up was 58 months (range 1-321). Adjuvant, neo-adjuvant chemotherapy and postoperative radiotherapy were administered in 112, 45 and 181 cases, respectively. In all, 59% of patients treated with chemotherapy received an ifosfamide-containing regimen. The 5-year OS, LRFS and DRFS rates were 64.0%, 70% and 57%, respectively. On multivariate analysis, age >35 years old, grade 3 and not-R0 margins were highly significant independent predictors of worse OS. After adjustment to prognostic factors, radiotherapy significantly improved LRFS but not DRFS or OS. Neither neo-adjuvant nor adjuvant chemotherapy had significant impact on OS, LRFS or DRFS. CONCLUSION: As for other high-grade soft-tissue sarcomas, well-planned wide surgical excision with adjuvant radiotherapy remains the cornerstone of treatment for SS. Neo-adjuvant or adjuvant chemotherapy should not be delivered outside a clinical trial setting.
Pubmed
Web of science
Open Access
Oui
Création de la notice
17/03/2009 15:19
Dernière modification de la notice
14/02/2022 7:53
Données d'usage